-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Maintains Hold on Supernus Pharmaceuticals, Raises Price Target to $55

Benzinga·12/19/2025 14:53:06
語音播報
Stifel analyst Annabel Samimy maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Hold and raises the price target from $50 to $55.